Payment overview · 2025
General Payments
$179,236.36
213 reported records · 29 companies
Healthcare provider profile · identity verified
Melhem Solh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTA, GA · NPI 1023282514
Verified facts
What the public records show
CMS Open Payments records show Melhem Solh, M.D. received $179,236.36 in general payments during 2025 across 213 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 41.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cresemba, Rezurock.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cresemba as an associated drug or biological on 2800 records involving 1563 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Cresemba by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REZUROCK as an associated drug or biological on 17 records involving 14 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rezurock by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jakafi by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REZUROCK as an associated drug or biological on 1398 records involving 724 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rezurock by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $75,111.79 | 41.9% | 33 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $34,800.34 | 19.4% | 53 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17,397.46 | 9.7% | 15 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $10,844.98 | 6.0% | 14 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $10,205.76 | 5.7% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $6,733.60 | 3.8% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $5,548.18 | 3.1% | 8 | 2025 |
| Pierre Fabre Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5,085.68 | 2.8% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $3,821.54 | 2.1% | 5 | 2025 |
| Legend Biotech USA Inc. | Unresolved — no canonical attribution shown | $3,607.20 | 2.0% | 13 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $2,999.26 | 1.7% | 8 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $629.11 | 0.3% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $544.56 | 0.3% | 9 | 2025 |
| Secura Bio, Inc. | Unresolved — no canonical attribution shown | $373.29 | 0.2% | 3 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $295.52 | 0.2% | 2 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $218.07 | 0.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $214.56 | 0.1% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $166.01 | 0.1% | 3 | 2025 |
| ADC THERAPEUTICS AMERICA, INC. | Unresolved — no canonical attribution shown | $161.91 | 0.1% | 2 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $159.91 | 0.1% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $62.84 | 0.0% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $59.78 | 0.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $54.62 | 0.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.01 | 0.0% | 1 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $26.32 | 0.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.51 | 0.0% | 1 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.15 | 0.0% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $19.64 | 0.0% | 1 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $18.76 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $135,395.75 | 41 |
| Consulting Fee | $22,987.00 | 9 |
| Travel and Lodging | $9,699.88 | 47 |
| Food and Beverage | $7,204.74 | 113 |
| Honoraria | $3,750.00 | 1 |
| Education | $198.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $40,026.30 | 20 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Biological, Drug | Janssen Biotech, Inc., Legend Biotech USA Inc. | $36,494.96 | 57 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $32,887.76 | 44 | 2025 |
Source payment records
|
|||||
| BREYANZI Normalized: breyanzi |
Biological | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $29,149.85 | 17 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $17,197.03 | 11 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $10,844.98 | 14 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $10,205.76 | 7 | 2025 |
Source payment records
|
|||||
| BLINCYTO Normalized: blincyto |
Biological | Amgen Inc. | $5,548.18 | 8 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC., Genmab U.S., Inc. | $4,450.65 | 9 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $4,000.00 | 1 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $2,831.31 | 5 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $2,654.99 | 4 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $1,734.79 | 6 | 2025 |
Source payment records
|
|||||
| COPIKTRA Normalized: copiktra |
Drug | Secura Bio, Inc. | $373.29 | 3 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $295.52 | 2 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological, Drug | Janssen Biotech, Inc. | $245.53 | 6 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $218.07 | 3 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $167.95 | 3 | 2025 |
Source payment records
|
|||||
| DEFITELIO Normalized: defitelio |
Drug | JAZZ PHARMACEUTICALS INC. | $166.01 | 3 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $159.91 | 2 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $159.91 | 2 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $159.91 | 2 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $62.84 | 3 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $39.64 | 2 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $32.18 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $31.01 | 1 | 2025 |
Source payment records
|
|||||
| ICLUSIG Normalized: iclusig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $30.35 | 1 | 2025 |
Source payment records
|
|||||
| Venclexta Normalized: venclexta |
Biological | Genentech USA, Inc. | $27.60 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Drug | Blueprint Medicines Corporation | $26.32 | 1 | 2025 |
Source payment records
|
|||||
| LIVTENCITY Normalized: livtencity |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| REZUROCK Normalized: rezurock |
Drug | SANOFI-AVENTIS U.S. LLC | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| ZYNLONTA Normalized: zynlonta |
Drug | ADC THERAPEUTICS AMERICA, INC. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| ELZONRIS Normalized: elzonris |
Drug | Stemline Therapeutics Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| Tibsovo Normalized: tibsovo |
Drug | SERVIER PHARMACEUTICALS LLC | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $15.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Cresemba cresemba |
2025 | Cresemba | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REZUROCK rezurock |
2025 | Rezurock | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Cresemba open payments reported associated product |
CMS Open Payments — General Payments 2800 supporting records · 1563 recipient NPIs · example record 1238560682 |
Cresemba · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | REZUROCK open payments reported associated product |
CMS Open Payments — General Payments 17 supporting records · 14 recipient NPIs · example record 1233208487 |
Rezurock · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
33 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | REZUROCK open payments reported associated product |
CMS Open Payments — General Payments 1398 supporting records · 724 recipient NPIs · example record 1233195188 |
Rezurock · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Acyclovir | Acyclovir | 146 | 68 |
| Tramadol Hcl | Tramadol Hcl | 63 | 42 |
| Levofloxacin | Levofloxacin | 43 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 42 | 20 |
| Potassium Chloride | Potassium Chloride | 40 | 25 |
| Famotidine | Famotidine | 39 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 31 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 15 |
| Jakafi | Ruxolitinib Phosphate | 33 | 17 |
| Penicillin V Potassium | Penicillin V Potassium | 27 | suppressed |
| Gabapentin | Gabapentin | 25 | 12 |
| Cresemba | Isavuconazonium Sulfate | 24 | suppressed |
| Posaconazole | Posaconazole | 24 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 23 | 22 |
| Fluconazole | Fluconazole | 18 | 17 |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 13 | suppressed |
| Atovaquone | Atovaquone | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 11 | suppressed |
| Rezurock | Belumosudil Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $179,236.36 · 213 records | E.R. Squibb & Sons, L.L.C. | ADCETRIS, AYVAKIT, Amtagvi, BLINCYTO, BREYANZI, CARVYKTI, COPIKTRA, Cresemba, DARZALEX, DATROWAY, DEFITELIO, ELREXFIO, ELZONRIS, EPKINLY, Gavreto, ICLUSIG, LIVTENCITY, MONJUVI, OJJAARA, Polivy, REBLOZYL, REZUROCK, RYBREVANT, Rezlidhia, SARCLISA, SCEMBLIX, TALVEY, TAVALISSE, TECVAYLI, Tibsovo, Vanflyta, Venclexta, XPOVIO, Yescarta, ZYNLONTA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cresemba play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error